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hiv/aids and malaria are two major global infectious diseases. Although better drugs against 
these conditions are becoming more available, dosages may not always be optimal with respect 
to effectiveness, safety, cost or convenience of administration. This thesis aims to quantitate the 
pharmacological relationship between dosing history, sources of variation between individuals, 
drug exposure and response to selected antiretroviral and antimalarial regimens. 
Pharmacometric, i.e. pharmaco-statistical, models were fitted to observed data from five clinical 
studies, using the nonmem software. Several polymorphic genes coding for drug metabolizing 
enzymes and transporters were found to have impact on the disposition of the non-nucleoside 
reverse transcriptase inhibitor efavirenz in healthy Ugandan subjects after single dose adminis-
tration. Moreover, using simulation it was demonstrated that a 200 mg dose reduction in Zim-
babwean hiv-patients with genetically decreased metabolic capacity would maintain efavirenz 
exposure within the therapeutic range during repeated administration. In a typical clinical trial 
large amounts of drug response data are collected. However, usually only limited amounts of the 
recorded data are actually used for investigating differences between regimens. Herein, a drug-
disease model was developed to describe the time-course of repeatedly measured hiv-rna levels 
in Scandinavian patients randomized to one of three commonly prescribed antiretroviral regi-
mens. The initial analysis showed that an efavirenz-containing regimen appeared to be more effi-
cacious compared to two protease inhibitor-containing regimens. Antimalarial artemisinin-based 
combination therapy bears many resemblances to antiretroviral treatment. The drugs exhibit vari-
able and complex pharmacokinetics and the diseases themselves bring reasonable possibilities for 
pharmacodynamic assessment. Auto-induction of drug metabolism was described after multiple 
dosing with artemisinin in Vietnamese patients. The frequency of recrudescent malaria infection 
was as high as 37% but could not directly be linked to low artemisinin exposure. The elimination 
half-life of piperaquine, a suitable partner drug for artemisinin-based combination treatment, was 
estimated to 12 days with large between-subject variability.
The thesis demonstrates the utility of pharmacometric methodology in the analysis of clinical 
data originating from high-income countries as well as resource-limited settings. Ultimately it can 
be a tool for decision analysis and policy making.
Keywords : hiv, malaria, pharmacokinetics, pharmacodynamics, pharmacometrics, nonmem
ISBN 978-91-628-7667-8
